Rockwell Medical, Inc. (RMTI)

Market Cap	69.81M
Revenue (ttm)	98.92M
Net Income (ttm)	-1.43M
Shares Out	32.32M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	509,079
Open	2.240
Previous Close	2.240
Day's Range	2.145 - 2.240
52-Week Range	1.160 - 5.150
Beta	1.37
Analysts	Strong Buy
Price Target	6.00 (+177.78%)
Earnings Date	Nov 12, 2024

About RMTI

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 27, 1998
• Employees: 237
• Stock Exchange: NASDAQ
• Ticker Symbol: RMTI
• Website: https://www.rockwellmed.com

Financial Performance

In 2023, Rockwell Medical's revenue was $83.61 million, an increase of 14.84% compared to the previous year's $72.81 million. Losses were -$8.59 million, -54.02% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for RMTI stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 177.78% from the latest price.

Price Target

$6.0

(177.78% upside)

Analyst Consensus: Strong Buy